-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$5.2881.44% Upside
Xeris Biopharma Holdings, Inc. Frequently Asked Questions
-
What analysts cover Xeris Biopharma Holdings, Inc.?
Xeris Biopharma Holdings, Inc. has been rated by research analysts at H.C. Wainwright, Oppenheimer, Piper Sandler, Craig-Hallum in the past 90 days.